Search

Your search keyword '"Antonio Vélez García-Nieto"' showing total 2 results
Start Over Author "Antonio Vélez García-Nieto" Journal anais brasileiros de dermatologia
2 results on '"Antonio Vélez García-Nieto"'

1. Alemtuzumab in refractory Sézary syndrome

Author

Carmen María Alcántara Reifs, Rafael Salido-Vallejo, Gloria María Garnacho-Saucedo, Sofía De la Corte-Sánchez, Alberto González-Menchen, and Antonio Vélez García-Nieto

Subjects
Antibodies, monoclonal, humanized, Lymphoma, T-Cell, cutaneous, Sézary syndrome, Treatment outcome, Dermatology, RL1-803
Abstract

Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.

Published
2016
Full Text
View/download PDF

2. Alemtuzumab in refractory Sézary syndrome

Author

Gloria Garnacho-Saucedo, Alberto González-Menchen, Carmen María Alcántara Reifs, Antonio Vélez García-Nieto, Rafael Salido-Vallejo, and Sofía de la Corte-Sánchez

Subjects
Antigens, Differentiation, T-Lymphocyte, Male, Pathology, medicine.medical_specialty, Skin Neoplasms, Erythroderma, Case Report, Antineoplastic Agents, Dermatology, Antibodies, Monoclonal, Humanized, 030207 dermatology & venereal diseases, 03 medical and health sciences, Antibodies, monoclonal, humanized, 0302 clinical medicine, Refractory, Antigen, medicine, Humans, Sezary Syndrome, Treatment outcome, Adverse effect, Alemtuzumab, Lymphoma, T-Cell, cutaneous, Aged, biology, business.industry, medicine.disease, Lymphoma, Blood Cell Count, Treatment Outcome, 030220 oncology & carcinogenesis, Sézary syndrome, RL1-803, Monoclonal, biology.protein, Antibody, business, medicine.drug
Abstract

Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results